OCRELIZUMAB | B761053 | GENENTECH INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Mar. 28, 2029 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12440525(method of use) · relevance 70/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 264 AI-discovered patents by relevance.
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Kaylin Bower FDA-2025-P-1093 Kaylin Bower, founder of an MS advocacy organization, filed a citizen petition requesting that the FDA amend the labeling for Ocrevus (ocrelizumab) to comply with 21 CFR 201.57(c)(2)(i)(B) by indicating in the "Indications and Usage" and "Clinical Studies" sections that the drug showed efficacy only | Other | 2025-04-17 | Open | Kaylin Bower |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.